Welcome to our dedicated page for GeoVax Labs New news (Ticker: GOVX), a resource for investors and traders seeking the latest updates and insights on GeoVax Labs New stock.
GeoVax Labs, Inc. (Nasdaq: GOVX) is a clinical-stage biotechnology company specializing in the development of human vaccines and immunotherapies against infectious diseases and cancers. Utilizing their innovative Modified Vaccinia Ankara-Virus-Like Particle (MVA-VLP) platform, GeoVax has a strong focus on creating vaccines that stimulate both humoral and cellular immune responses to various targeted infections.
GeoVax's product pipeline includes an advanced Covid-19 vaccine, GEO-CM04S1, which is currently undergoing three phase 2 clinical trials. This next-generation vaccine is designed to induce robust antibody and T-cell responses against multiple SARS-CoV-2 variants, including Delta and Omicron. GEO-CM04S1 is especially targeted at high-risk immunocompromised populations who may not respond adequately to existing vaccines.
In oncology, GeoVax is pioneering novel therapies with Gedeptin®, an oncolytic gene-directed therapy for solid tumors. Gedeptin® is in phase 1/2 clinical trials for advanced head and neck cancers, aiming to provide new treatment avenues for patients with limited options.
GeoVax has shown significant progress in vaccine development against other infectious diseases such as Mpox, smallpox, HIV, Zika, hemorrhagic fever viruses, and malaria. Their recent partnership with the National Institute of Allergy and Infectious Diseases (NIAID) has expanded their vaccine development license to include Mpox and smallpox, leveraging their MVA technology for broader immunological protection.
The company also focuses on intellectual property, holding over 115 granted or pending patents across 24 patent families. This robust IP portfolio enhances their competitive edge in the biopharmaceutical sector.
GeoVax's commitment to innovative research and scalable manufacturing solutions positions them as a key player in the fight against some of the world’s most threatening diseases. For more detailed information, visit their official website at www.geovax.com.
GeoVax Labs, Inc. (Nasdaq: GOVX) reported its Q2 2024 financial results and provided a business update. Key highlights include:
1. Awarded BARDA Project NextGen (PNG) contract worth over $350 million to advance GEO-CM04S1, their next-generation COVID-19 vaccine, into a 10,000-participant Phase 2b study.
2. Partnered with Allucent, a global CRO, to conduct the Phase 2b trial.
3. Advancing Gedeptin® into an expanded Phase 2 clinical trial for first-recurrence head and neck cancer, with activation expected in H1 2025.
4. Produced first lot of GEO-CM04S1 with a commercial manufacturing platform.
5. Q2 2024 net loss of $5,064,042 ($1.99 per share), compared to $5,927,620 ($3.79 per share) in Q2 2023.
6. Cash balance of $1,561,712 as of June 30, 2024.
GeoVax Labs, Inc. (Nasdaq: GOVX) has announced plans for a Phase 2 trial of its Gedeptin® cancer therapy following a clinical advisory committee review. The trial will focus on first-recurrence head and neck cancer, combining Gedeptin with an immune checkpoint inhibitor. This decision comes after reviewing the completed PNP-002 Phase 1b/2a and PNP-001 Phase 1 trials, which demonstrated acceptable safety and efficacy in advanced head and neck squamous cell carcinoma (HNSCC) patients.
The planned Phase 2 trial aims to establish the efficacy of neoadjuvant Gedeptin therapy combined with an immune checkpoint inhibitor. It will involve approximately 6 patients, with pathologic response rate as the primary endpoint. GeoVax anticipates trial activation during the first half of 2025. The company is also pursuing development plans for Gedeptin in additional solid tumor indications in partnership with leading academic oncology centers.
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases, has announced it will release its second quarter 2024 financial results on Tuesday, August 6, 2024, after U.S. markets close. The company will host a live conference call and webcast at 4:30 p.m. ET on the same day to discuss the financial results and provide a corporate update.
Investors and interested parties can join the conference call using the following details:
- Domestic: (800) 715-9871
- International: +1 (646) 307-1963
- Conference ID: 3852178
A webcast of the call will be available at https://edge.media-server.com/mmc/p/qj3e68n8, with a replay accessible for three months after the event.
FAQ
What is the current stock price of GeoVax Labs New (GOVX)?
What is the market cap of GeoVax Labs New (GOVX)?
What is GeoVax Labs, Inc.?
What is the MVA-VLP platform?
What are the main products in GeoVax’s pipeline?
What is the current status of the GEO-CM04S1 vaccine?
What is Gedeptin®?
How does GeoVax’s partnership with NIAID benefit their technology?
What recent achievements has GeoVax announced?
How extensive is GeoVax’s intellectual property portfolio?
What is the significance of GeoVax’s Covid-19 vaccine?
How can I learn more about GeoVax Labs, Inc.?
